Covira is an early-stage biotech company, a spinout from The University of Chicago (Sept 2018). This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira's focus is to develop drugs that work by modulating the biological activity of the gut microbiome's resident bacteria. Covira’s lead asset (CS-0003) is a platform technology that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. CS-0003 is transformative to the field and the world is taking notice...in the 4th quarter of last year Business Worldwide Magazine named Covira Among the 2021- Top 20 Most Innovative Companies to Watch.